ImmuPharma (LON:IMM) Trading 33.3% Higher – Should You Buy?

Shares of ImmuPharma plc (LON:IMMGet Free Report) rose 33.3% on Friday . The company traded as high as GBX 3.59 ($0.04) and last traded at GBX 3.50 ($0.04). Approximately 3,166,375 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 22,823,164 shares. The stock had previously closed at GBX 2.63 ($0.03).

ImmuPharma Stock Performance

The company has a market cap of £13.95 million, a price-to-earnings ratio of -335.00 and a beta of 1.53. The firm’s 50 day simple moving average is GBX 1.59 and its 200-day simple moving average is GBX 1.69.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.